Metabolic syndrome: Definition, history, criterion;Síndrome metabólico: Definición, historia, criterios

Colombia Medica

Volumn 39, Issue 1, 2008, Pages 96-106

  Pineda, Carlos Andrés ^a  

^a UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

Dislypidemia; Hyperglycemic; Insuline resistence; Metabolic syndrome; Obesity

Indexed keywords

CARBOHYDRATE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; URIC ACID;

ACANTHOSIS NIGRICANS; AGE; ARTERIAL PRESSURE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DYSLIPIDEMIA; ETHNIC GROUP; GENDER; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOTHYROIDISM; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; LIPID METABOLISM; MEDLINE; METABOLIC SYNDROME X; MICROALBUMINURIA; NOMENCLATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; REVIEW; RISK FACTOR; STRESS; SYNDROME X; THROMBOGENESIS; WORLD HEALTH ORGANIZATION;

EID: 41649096106     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Vélez LF, Gracia B. La selección do los alimentos: una práctica compleja. Colomb Med. 2003; 34: 92-6.
2. Departamento Administrativo Nacional de Estadística (DANE). (fecha do acceso julio 19 de 2006). Disponible en: http://www.dane.gov.co/index.php?option=com content&task= category§ionid=16&id=217& Itemid=647
3. Cupples LA, D'Agostino RB. Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, editors. Framingham Heart Study: 30 year follow-up. Bethesda: US Department of Health and Human Services; 1987.
4. Meisinger C, Koletzko B, Heinrich J. Metabolic syndrome: Older than usually assumed, but still too young to die. Clin Chem. 2006; 52: 897-8.
5. Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity. In: Joannes Baptista. Morgagni's 'De sedibus et causis morborum per anatomen indagata'. Int J Obes Relat Metab Disord. 2003; 27: 534-5.
6. Reaven G, Calciano A, Cody R, Lucas C, Millar R. Carbohydrate intolerant and hyperlipemia in patients with myocardial infarction without known diabetes mellitus. J Clin Endocrinol Metab. 1963; 23: 1013-23.
7. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974; 57: 551-60.
8. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-607.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15: 539-53.
10. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106: 3143-421.
11. Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B, et al. AHA/NHLBI Scientific statement. Diagnosis and management of the metabolic syndrome. Circulation. 2005; 112: 2735-52.
12. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16: 442-3.
13. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus-American Diabetes Association. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
14. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003; 9: 237-52.
15. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. (fecha de acceso julio 22 de 2006). Disponible en: http://www.idf.org/webdata/docs/ IDF_Metasyndrome_definition.pdf
16. Pouliot MC, Després JP, Lemieux S, Moorjani S, Bouchard C, Trembloy A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994; 73: 460-8.
17. Asociación Colombiana de Endocrinología. (fecha de acceso en julio 22 de 2006). Disponible en: http://www.endocrino.org.co/ ronda.htm
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-64.
19. Martínez-Candela J, Franch-Nadal J, Romero-Ortiz J, Cánovas-Domínguez C, Gallardo-Martín A, Páez-Pérez M. Prevalence of metabolic syndrome in the adult population of Yecla (Murcia). Degree of agreement between three definitions. Aten Primaria. 2006; 38: 72-9.
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85: 2402-10.
21. Carr D, Utzschneider K, Hull R, Kodama K, Retzlaff BM, Bruozel JA, et al. Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel criteria for the metabolic syndrome. Diabetes. 2004; 53: 2087-94.
22. Wagenknecht L, Langefeld C, Scherzinger A, Norris J, Haffner S, Saad M, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003; 52: 2490-6.
23. McTigue K, Harris R, Hemphill B, Lux L, Sutton S, Bunton A, et al. Screening and interventions for obesity in adults: Summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003; 139: 933-49.
24. Calle EE, Thun MJ, Petrelli JM, Rodríguez C, Heath CWJr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341: 1097-105.
25. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among US adults. Obes Res. 2003; 11: 1223-31.
26. Pérez M, Casas JP, Cubillos-Garzón LA, Serrano NC, Silva F, Morillo CA, et al. Using waist circumfereuce as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovas Preven Rehab. 2003; 10: 328-35.
27. López-Jaramillo P, Rueda-Clausen CF, Silva FA. The utility of different definitions of metabolic syndrome in an Andean population. Intl J Cardiol. 2007; 116: 421 22.
28. Sattar N, Williams K, Sniderman A, D' Agostino R, Haffner S. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the insulin resistance atherosclerosis study. Circulation. 2004; 110: 2687-93.
29. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation. 2004; 109: 42-6.
30. McLaughlin T, Abbasi F Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003; 139: 802-9.
31. US Department of Health and Human Services. National Institute of Health, National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection and Treatment of High Blood Pressure. [en línea]. May 2003. [fecha de acceso 24 julio de 2006]. Disponible en: http://www.nhlbi.nih.gov/ guidelines/hypertension/jnc7full.htm
32. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 1011-53.
33. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 161: 397-404.
34. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003; 26: 688-96.
35. Reaven G. Metabolic syndrome pathophysiology and implications for management of cardiovascular disease. Circulation. 2002; 106: 286-8.
36. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000; 152: 897-907.
37. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute phase proteins and PAI-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51: 1131-7.
38. Ross R. Atherosclerosis -an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
39. Lowe GD, Rumley A, Wannamethee SG. Haemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost. 2005; 3: 1076-8.
40. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Center for Disease Control and Prevention and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice -a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
41. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. PCreactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387-97.
42. Ridker P, Buring J, Cook N, Rifai N. PC-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003; 107: 391-7.
43. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004; 109: 837-42.
44. Ridker P, Rifai N, Rose L, Buring J, Cook N. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557-65.
45. Carnethon MR, Fortmann SP, Palaniapan L, Duncan BB, Schmidt MI, Chambless LE. Risk Factors for progression to incident hyperinsulinemia: the atherosclerotic risk in communities study, 1997-1998. Am J Epidemiol. 2003; 158: 1058-67.
46. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11,119 cases and 13,648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 953-62.
47. Hemingway H, Marmot M. Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. BMJ. 1999; 318: 1460-17.
48. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation. 2005; 112: 505-12.
49. Lord J, Flight I, Norman R. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003; 327: 951-7.
50. Smith S, Clark L, Cooper R, Daniels S, Kumanyika S, Ofili E, et al. Discovering the full spectrum of cardiovascular disease minority health summit 2003 Report of the obesity, metabolic syndrome, and hypertension writing group. Circulation. 2005; 111: e134-e9.